Minimal tolerance to the bronchoprotective effect of inhaled salmeterol/fluticasone combination on allergene challenge

Pulmonary Pharmacology and Therapeutics

Volumn 19, Issue 6, 2006, Pages 425-429

  Paggiaro, P L ^a   Giannini, D ^b   Di Franco, A ^a   Bacci, E ^a   Dente, F L ^a   Vagaggini, B ^a   Tonelli, M ^a   Zingoni, M ^a  

^a UNIVERSITY OF PISA   (Italy)

^b CISANELLO HOSPITAL   (Italy)

Author keywords

Allergen challenge; Combination therapy; Fluticasone; Salmeterol; Tolerance

Indexed keywords

ALLERGEN; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; FLUTICASONE PROPIONATE; IPRATROPIUM BROMIDE; PLACEBO; SALMETEROL;

ADULT; AIRWAY; ALLERGIC ASTHMA; AREA UNDER THE CURVE; ARTICLE; BRONCHOSPASM; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE SEVERITY; DRUG EFFECT; DRUG TOLERANCE; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; MALE; PRIORITY JOURNAL; PROTECTION; PROVOCATION TEST; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SINGLE DRUG DOSE; TREATMENT DURATION;

ADMINISTRATION, INHALATION; ADULT; ALBUTEROL; ALLERGENS; ANDROSTADIENES; ASTHMA; BRONCHODILATOR AGENTS; CROSS-OVER STUDIES; DRUG TOLERANCE; FEMALE; HUMANS; MALE; RESPIRATORY FUNCTION TESTS; SINGLE-BLIND METHOD;

EID: 33747204021     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2005.10.006     Document Type: Article

References (33)

1. Cheung D., Timmers M.C., Zwindmerman A.H., et al. Long-term effect of a long-acting ß2-adrenoceptor agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma. N Engl J Med 327 (1992) 1198-1203
2. Ramage L., Lipworth B.J., Ingram C.G., et al. Reduced protection against exercise induced bronchoconstriction after chronic dosing with salmeterol. Resp Med 88 (1994) 363-368
3. Giannini D., Carletti A., Dente F.L., et al. Tolerance to the bronchoprotective effect of salmeterol on allergen challenge. Chest 110 (1996) 1452-1457
4. Hui K.P.P., Conolly M.E., and Tashkin D.P. Reversal of human lymphocyte ß-adrenoceptor desensitization by glucocorticosteroids. Clin Pharmacol Ther 32 (1982) 566-571
5. Brodde O.-E., Brinkmann M., Schemuth R., et al. Terbutaline-induced desensitization of human lymphocyte ß2-adrenoceptor. Accelerated restoration of ß-adrenoceptor responsiveness by prednisone and ketotifen. J Clin Invest 76 (1985) 1096-1101
6. Davies A.O., and Lefkowitz R.J. In vitro desensitization of beta-adrenergic receptors in human neutrophils: attenuation by corticosteroids. J Clin Invest 71 (1983) 565-571
7. Ellul-Micallef R., and Fenech F.F. Effect of intravenous prednisolone in asthmatics with diminished adrenergic responsiveness. Lancet ii (1975) 1269-1271
8. Booth H., Bish R., Walters J., et al. Salmeterol tachyphylaxis in steroid treated asthmatic subjects. Thorax 51 (1996) 1100-1104
9. Giannini D., Bacci E., Dente F.L., et al. Inhaled beclomethasone dipropionate reverts tolerance to the protective effect of salmeterol on allergen challenge. Chest 115 (1999) 629-634
10. Nationa Institutes of Health. Global strategy for asthma management and prevention. NIH publication No 02-3659, February 2002.
11. Paggiaro P.L., Dente F.L., Talini D., et al. Pattern of airway response to allergen extract of phleum pratensis in asthmatic patients during and outside the pollen season. Respiration 57 (1990) 51-56
12. Siegel S., and Castellan N.J. Nonparametric Statistics for the behavioral sciences. 2nd ed (1992), McGraw-Hill Libri Italia Rrl, Milano
13. Anderson S., Seale J.P., Ferris L., Shoefflel R., and Lindsay D.A. An evaluation of pharmacotherapy for exercise-induced asthma. J Allergy Clin Immunol 64 (1979) 612-624
14. Karla S., Swystun V.A., Bhagat R., et al. Inhaled corticosteroids do not prevent the development of tolerance to the bronchoprotective effect of salmeterol. Chest 109 (1996) 953-956
15. Boulet L.P., Cartier A., Milot J., et al. The to the protective effects of salmeterol on methacholine-induced bronchoconstriction: influence of inhaled corticosteroids. Eur Respir J 11 (1998) 1091-1097
16. O'Connor B.J., Aikman S.L., and Barnes P.J. Tolerance to the nonbronchodilator effects of inhaled b2-agonists in asthma. N Engl J Med 327 (1992) 1204-1208
17. Haney S., and Hancox R.J. Rapid onset of tolerance to beta-agonist bronchodilation. Respir Med 99 (2005) 566-571
18. Lazarus S.C., Boushey H.A., Fahy J.V., et al. Long-acting β2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma. A randomized controlled trial. JAMA 285 (2001) 2583-2593
19. Aziz I., Tan K.S., Hall I.P., Devlin M.M., and Lipworth B.J. Subsensitivity to bronchoprotection against adenosine monophosphate challenge following regular once-daily formoterol. Eur Respir J 12 (1998) 580-584
20. Grootendorst D.C., Sterk P.J., and Heijerman H.M.G. Effect of oral prednisolone on the bronchoprotective effect of formoterol in patients with persistent asthma. Eur Respir J 17 (2001) 374-379
21. Eickelberg O., Roth M., Lorx R., et al. Ligand-independent activation of the glucocorticoid receptor by b2-adrenergic agonists in primari human lung fibroblasts and vascular smooth muscle cells. J Biol Chem 274 (1999) 1005-1010
22. Pang L., and Knox A.J. Regulation of TNF-a-induced eotaxin release from cultured human airway smooth muscle by b2-agonists and corticosteroids. FASEB J 15 (2001) 261-269
23. Korn S.H., Jerre A., and Brattsand R. Effects of formoterol and budesonide on GM-CSF and IL-8 secretion by triggered human bronchil epithelial cells. Eur Respir J 17 (2001) 1070-1077
24. Roth M., Johnson P.R., Rudiger J.J., et al. Interaction between glucocorticosteroids and b2-agonists on bronchial airway smooth muscle cells through synchronised cellular signalling. Lancet 360 (2002) 1293-1299
25. Giannini D., Di Franco A., Bacci E., et al. Tolerance to the protective effect of salmeterol in mild untreated asthmatics. Pulm Pharmacol Ther 16 (2003) 355-360
26. Dahl R., and Johansson S.-A. Importance of duration of treatment with inhaled budesonide on the immediate and late bronchial reaction. Eur J Respir Dis 63 suppl 122 (1982) 167-175
27. Inman M.D., Watson R.M., Rerecich T., et al. Dose-dependent effects of inhaled mometasone furoate on airway function and inflammation after allergen inhalation challenge. Am J Respir Crit Care Med 164 (2001) 569-574
28. Leigh R., Vethanayagam D., Yoshida M., et al. Effects of montelukast and budesonide on airway responses and airway inflammation in asthma. Am J Respir Crit Care Med 166 (2002) 1212-1217
29. Palmqvist M., Bruce C., Sjostrand M., Arvidsson P., and Lotvall J. Differential effects of fluticasone and montelukast on allergen-induced asthma. Allergy 60 (2005) 65-70
30. Hancox R.J., Sears M.R., and Taylor D.R. Polymorphism of the beta2-adrenoreceptor and the response to long-term beta2-agonist therapy in asthma. Eur Respir J 11 (1998) 589-593
31. Lee D.K.C., Jackson C.M., Bates C.E., and Lipworth B.J. Cross tolerance to salbutamol occurs independently of beta2-adrenoreceptor genotype-16 in asthmatic patients receiving regular formoterol or salmeterol. Thorax 59 (2004) 662-667
32. Pauwels R.A., Lofdhal C.G., Postma D.S., et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med 337 (1997) 1405-1411
33. Shrewsbury S., Pyke S., and Britton M. Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA). BMJ 320 (2000) 1368-1373